Wells Fargo & Company Iovance Biotherapeutics, Inc. Put Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding IOVA
# of Institutions
323Shares Held
239MCall Options Held
1.27MPut Options Held
1.68M-
Vanguard Group Inc Valley Forge, PA26MShares$268 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY25.9MShares$268 Million6.02% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$248 Million28.39% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$219 Million0.0% of portfolio
-
State Street Corp Boston, MA12.6MShares$131 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.63B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...